Sera Prognostics, Inc. (SERA)
USD 3.4
(1.49%)
USD 3.4
(1.49%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.85 Million USD | -19.64% |
| 2022 | 2.31 Million USD | 1706.25% |
| 2021 | 128 Thousand USD | -98.52% |
| 2020 | 8.67 Million USD | -6.89% |
| 2019 | 9.31 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.61 Million USD | -13.35% |
| 2024 Q2 | 1.35 Million USD | -15.71% |
| 2023 Q4 | 1.85 Million USD | 20.73% |
| 2023 Q2 | 2.35 Million USD | 14.77% |
| 2023 FY | 1.85 Million USD | -19.64% |
| 2023 Q1 | 2.05 Million USD | -11.29% |
| 2023 Q3 | 1.53 Million USD | -34.62% |
| 2022 Q2 | 1.6 Million USD | 5.81% |
| 2022 FY | 2.31 Million USD | 1706.25% |
| 2022 Q1 | 1.51 Million USD | 1083.59% |
| 2022 Q3 | 1.35 Million USD | -15.35% |
| 2022 Q4 | 2.31 Million USD | 70.38% |
| 2021 Q2 | 162 Thousand USD | -86.82% |
| 2021 Q3 | 145 Thousand USD | -10.49% |
| 2021 Q4 | 128 Thousand USD | -11.72% |
| 2021 FY | 128 Thousand USD | -98.52% |
| 2021 Q1 | 1.22 Million USD | -85.83% |
| 2020 FY | 8.67 Million USD | -6.89% |
| 2020 Q4 | 8.67 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | 9.31 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 426 Thousand USD | -336.15% |
| Applied DNA Sciences, Inc. | 1.23 Million USD | -50.11% |
| Aspira Women's Health Inc. | 2.26 Million USD | 18.005% |
| Biodesix, Inc. | 60.69 Million USD | 96.939% |
| BioNexus Gene Lab Corp. | 133.39 Thousand USD | -1292.856% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -17.696% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -17.696% |
| Bionano Genomics, Inc. | 87.94 Million USD | 97.887% |
| CareDx, Inc | 34.22 Million USD | 94.571% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 15.31 Million USD | 87.864% |
| DarioHealth Corp. | 29.54 Million USD | 93.71% |
| Exact Sciences Corporation | 2.55 Billion USD | 99.927% |
| Fulgent Genetics, Inc. | 14.9 Million USD | 87.536% |
| Guardant Health, Inc. | 1.35 Billion USD | 99.863% |
| ICON Public Limited Company | 3.93 Billion USD | 99.953% |
| IDEXX Laboratories, Inc. | 947.88 Million USD | 99.804% |
| Illumina, Inc. | 2.26 Billion USD | 99.918% |
| Intelligent Bio Solutions Inc. | 871.44 Thousand USD | -113.21% |
| iSpecimen Inc. | 196.24 Thousand USD | -846.781% |
| Standard BioTools Inc. | 98.21 Million USD | 98.108% |
| MDxHealth SA | 41.26 Million USD | 95.497% |
| 23andMe Holding Co. | 76.51 Million USD | 97.572% |
| Medpace Holdings, Inc. | 142.12 Million USD | 98.693% |
| Myriad Genetics, Inc. | 145 Million USD | 98.719% |
| Mainz Biomed B.V. | 7.42 Million USD | 74.962% |
| ENDRA Life Sciences Inc. | 394.4 Thousand USD | -371.092% |
| NeoGenomics, Inc. | 611.67 Million USD | 99.696% |
| Neogen Corporation | 906.23 Million USD | 99.795% |
| Inotiv, Inc. | 417.64 Million USD | 99.555% |
| Natera, Inc. | 441.99 Million USD | 99.58% |
| OpGen, Inc. | 13.04 Million USD | 85.756% |
| OPKO Health, Inc. | 326.56 Million USD | 99.431% |
| Psychemedics Corporation | 2.29 Million USD | 19.147% |
| Prenetics Global Limited | 2.36 Million USD | 21.583% |
| Prenetics Global Limited | 2.36 Million USD | 21.583% |
| Precipio, Inc. | 1.11 Million USD | -66.487% |
| Personalis, Inc. | 48.96 Million USD | 96.205% |
| RadNet, Inc. | 1.49 Billion USD | 99.875% |
| Sotera Health Company | 2.32 Billion USD | 99.92% |
| Neuronetics, Inc. | 62.47 Million USD | 97.026% |
| Star Equity Holdings, Inc. | 3.6 Million USD | 48.518% |
| Star Equity Holdings, Inc. | 3.6 Million USD | 48.518% |
| Trinity Biotech plc | 67.42 Million USD | 97.244% |
| T2 Biosystems, Inc. | 49.49 Million USD | 96.246% |
| Twist Bioscience Corporation | 94.06 Million USD | 98.025% |
| Exagen Inc. | 23.72 Million USD | 92.167% |